Silencing of circular RNA circPDE5A suppresses neuroblastoma progression by targeting the miR-362-5p/NOL4L axis

Chen, Yongcun; Lin, Liangfeng; Hu, Xiaohao; Li, Qiaoyu; Wu, Min

doi:10.1080/00207454.2021.1896505

Cited by 7 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Circular RNAs might also be considered as regulators of translation [53][54][55][56]. CircRNA-TBC1D4, circRNA-NAALAD2, and circRNA-TGFBR3 may be tumor suppressor genes in neuroblastoma.…”

Section: Discussionmentioning

confidence: 99%

“…If downregulated simultaneously, they may serve as biomarkers of unfavorable neuroblastoma [53]. Other circular RNAs might act as oncogenes: circ_0132817 facilitates cell proliferation, migration, invasion, and glycolysis in neuroblastoma [54]; circPDE5A is upregulated in neuroblastoma tissues and cells and its silencing suppresses neuroblastoma cell proliferation, migration, invasion, and glycolysis in vitro and reduces tumor growth in vivo [55]; circular RNAs with oncogenic properties might even result from MYCN amplification in neuroblastoma cells [56].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

In Vitro Assessment of the Role of p53 on Chemotherapy Treatments in Neuroblastoma Cell Lines

et al. 2021

View full text Add to dashboard Cite

Neuroblastoma is the most frequent malignant extracranial solid tumor of infancy. The overall objective of this work consists of determining the presence of alterations in the p53/MDM2/p14ARF signaling pathway in neuroblastoma cell lines and deciphering their possible relationship with resistance to known antineoplastic drugs and to differentiation agents. Firstly, we characterized 10 neuroblastoma cell lines for alterations at the p53/MDM2/p14ARF signaling pathway by analysis of TP53 point mutations, MYCN and MDM2 amplification, and p14ARF methylation, homozygous deletions, and expression. Secondly, we chose SK-N-FI (mutated at TP53) and SK-N-Be(2) (wild-type TP53) cell lines, treated them with chemotherapeutic agents (doxorubicin, etoposide, cisplatin, and melphalan) and with two isomers of retinoic acid (RA): (9-cis and all-trans). Finally, we analyzed the distribution of the cell cycle, the induction of apoptosis, and the expression levels of p53, p21, and Bcl-2 in those two cell lines. P14ARF did not present promoter methylation, homozygous deletions, and protein expression in any of the 10 neuroblastoma cell lines. One TP53 point mutation was detected in the SK-N-FI cell line. MYCN amplification was frequent, while most cell lines did not present MDM2 amplification. Treatment of SK-N-FI and SK-N-Be(2) cells with doxorubicin, etoposide, cisplatin, and melphalan increased apoptosis and blocked the cycle in G2/M, while retinoic acid isomers induced apoptosis and decreased the percentage of cells in S phase in TP53 mutated SK-N-FI cells, but not in TP53 wild-type SK-N-Be(2) cells. Treatment with cisplatin, melphalan, or 9-cis RA decreased p53 expression levels in SK-N-FI cells but not in SK-N-Be (2). The expression of p21 was not modified in either of the two cell lines. Bcl-2 levels were reduced only in SK-N-FI cells after treatment with cisplatin. However, treatments with doxorubicin, etoposide, or 9-cis-RA did not modify the levels of this protein in either of the two cell lines. In conclusion, TP53 mutated SK-N-FI cells respond better to the retinoic isomers than TP53 wild-type SK-N-Be(2) cells. Although these are in vitro results, it seems that deciphering the molecular alterations of the p53/MDM2/p14ARF signaling pathway prior to treating patients of neuroblastoma might be useful for standardizing therapies with the aim of improving survival.

show abstract

“…Circular RNAs might also be considered as regulators of translation [53][54][55][56]. CircRNA-TBC1D4, circRNA-NAALAD2, and circRNA-TGFBR3 may be tumor suppressor genes in neuroblastoma.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

In Vitro Assessment of the Role of p53 on Chemotherapy Treatments in Neuroblastoma Cell Lines

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In the first work, miR-362-5p, which has suppressive functions in NB progression, was sponged by circRNA phosphodiesterase 5 A (circPDE5A, has_circ_0002474), which, in turn, was upregulated in NB cells and tissues. Among the functional targets of miR-362-5p, the authors identified NOL4L, whose expression correlates with the circPDE5A levels in NB [46]. In the second work, NOL4L was negatively regulated by miR-432-5p and positively regulated by circ_0132817.…”

Section: Neuroblastomamentioning

confidence: 94%

An Update on Circular RNA in Pediatric Cancers

et al. 2022

View full text Add to dashboard Cite

Circular RNAs (circRNAs) are a class of single-stranded closed noncoding RNA molecules which are formed as a result of reverse splicing of mRNAs. Despite their relative abundance, only recently there appeared an increased interest in the understanding of their regulatory importance. Among their most relevant characteristics are high stability, abundance and evolutionary conservation among species. CircRNAs are implicated in several cellular functions, ranging from miRNA and protein sponges to transcriptional modulation and splicing. Additionally, circRNAs’ aberrant expression in pathological conditions is bringing to light their possible use as diagnostic and prognostic biomarkers. Their use as indicator molecules of pathological changes is also supported by their peculiar covalent closed cyclic structure which bestows resistance to RNases. Their regulatory role in cancer pathogenesis and metastasis is supported by studies involving human tumors that have investigated different expression profiles of these molecules. As endogenous competitive RNA, circRNAs can regulate tumor proliferation and invasion and they arouse great consideration as potential therapeutic biomarkers and targets for cancer. In this review, we describe the most recent findings on circRNAs in the most common pediatric solid cancers (such as brain tumors, neuroblastomas, and sarcomas) and in more rare ones (such as Wilms tumors, hepatoblastomas, and retinoblastomas).

show abstract

“…Chen et al. reported the molecular role of circPDE5A in the NB malignant progression ( 32 ). In their investigation, circPDE5A expression was higher in NB tissues and cells.…”

Section: Carcinogenic Circrnasmentioning

confidence: 99%

Recent advances and application value of circRNA in neuroblastoma

Tan

Yang

2023

Front. Oncol.

View full text Add to dashboard Cite

Neuroblastoma (NB) is children’s most prevalent solid malignant tumor, accounting for 15% of childhood cancer mortality. Non-coding RNA is important in NB pathogenesis. As a newly identified non-coding RNA, abnormal regulation (abnormal up-regulation or down-regulation) of the circRNAs expression is implicated in the tumorigenesis of various tumors, including NB. CircRNAs primarily regulate the expression of microRNA (miRNA) target genes by microRNA (miRNA) sponge adsorption. Clinical evidence suggests that the expression of certain circRNAs is associated with the prognosis and clinical features of NB and hence may be exploited as a biomarker or therapeutic target. This review examines circRNAs that have been demonstrated to play a function in NB.

show abstract

Silencing of circular RNA circPDE5A suppresses neuroblastoma progression by targeting the miR-362-5p/NOL4L axis

Cited by 7 publications

References 31 publications

In Vitro Assessment of the Role of p53 on Chemotherapy Treatments in Neuroblastoma Cell Lines

In Vitro Assessment of the Role of p53 on Chemotherapy Treatments in Neuroblastoma Cell Lines

An Update on Circular RNA in Pediatric Cancers

Recent advances and application value of circRNA in neuroblastoma

Contact Info

Product

Resources

About